Abbott Labs (ABT) recent acquisition of Solvay is a lead indicator for a new wave of acquisitions of Biotech companies by Large Pharmaceutical companies like Pfizer (PFE), Bristol Myers (BMY) and Novartis (NVS) according to Serge Depatie, portfolio manager for NatCan Investments.  One target that Mr. Depatie thinks will make a good acquisition is Orexigen (OREX) which is focused on obesity treatments.

This entry was posted on Friday, October 23rd, 2009 at 12:59 pm and is filed under Healthcare Stocks. You can follow any responses to this entry through the RSS 2.0 feed.